6perAI
Clinical AI that prolongs treatment persistence
6perAI is an on-premise artificial intelligence platform for private hospitals that boosts therapeutic persistence in chronic patient care.
Embracing the era of 6P medicine (Personalized, Predictive, Preventive, Participatory, Population-based, and Persistence), 6perAI empowers healthcare teams to make data-driven decisions using real-world evidence from their own hospital.
The result: more effective, safer, and sustainable treatments, with patients staying on therapy long enough to achieve the best clinical outcomes.
The problem of poor treatment compliance in chronic diseases
It is estimated that up to half of chronic patients do not follow their treatment as prescribed, undermining therapy effectiveness and leading to complications. Inadequate long-term adherence carries enormous costs: in Spain alone, medication non-adherence causes around 18,400 premature deaths and about €11.25 billion in avoidable healthcare costs each year. Across Europe, non-adherence is estimated to burden health systems with €125 billion annually and contributes to roughly 200,000 premature deaths per year.
6perAI closes this gap through innovative digital health software that analyzes therapeutic persistence (the actual duration patients remain on treatment) for each therapy in clinical practice. By pinpointing where, when, and why patients discontinue their medications, the platform enables proactive interventions to improve adherence and extend persistence. This translates into more stable patients, fewer relapses and hospitalizations, and a tangible improvement in hospital ROI thanks to more efficient resource utilization. With 6perAI, your hospital can maximize the clinical and economic value of every therapy, delivering data-driven, outcome-focused care excellence.
Product
6perAI combines data science and clinical insight in one comprehensive solution that is easy to deploy. It is installed on the hospital’s own servers (on-premises), ensuring data security and privacy. Using existing information (EHR records, pharmacy dispensation data, etc.), 6perAI autonomously analyzes how each treatment performs in real-world conditions. Its key features include:
-
Therapeutic Persistence Evaluation
The system calculates the persistence rate for each therapy, measuring how long patients remain on treatment. It employs advanced techniques like Kaplan–Meier curves to visualize treatment “survival” over time, helping identify critical points where drop-offs occur. -
Predictive AI algorithms
6perAI uses machine learning models trained on the hospital’s historical data to predict patients’ risk of treatment dropout. This allows the care team to be alerted to at-risk patients or cohorts that may not sustain their therapy, enabling early, targeted interventions. -
3-in-1 Analysis (Efficacy, Safety, Adherence)
For each drug or regimen, the platform evaluates three fundamental dimensions: effectiveness (clinical outcomes achieved), safety (adverse event profile), and patient satisfaction/adherence. This holistic view determines the real-world therapeutic value of each option. -
Treatment Comparisons and Rankings
6perAI generates reports and visualizations comparing the persistence and outcomes of different therapeutic alternatives for the same condition. For example, you can see which biologic drug for arthritis achieves higher average persistence and why (e.g. lower toxicity or greater convenience), helping select the optimal option for each patient profile. -
Intuitive Dashboard
Information is presented via interactive dashboards and clear charts, accessible to hospital pharmacists, clinicians, and administrators alike. Users can filter results by disease, line of therapy, patient subgroup (naïve vs. refractory), and more, tailoring the analysis to the needs of each therapeutics committee. -
Continuous Updates
As new patient data accumulates, 6perAI automatically recalculates persistence metrics and updates its predictive models. Knowledge is always up-to-date, reflecting the hospital’s evolving reality in near real-time. -
Integration and Support
6perAI integrates smoothly with hospital information systems (HL7, FHIR, SQL databases, etc.) without disrupting existing workflows. The 6perAI team provides full support during deployment, user training, and ongoing technical assistance to ensure the tool delivers maximum value.
Technology
6perAI is built with cutting-edge AI technology tailored for healthcare, meeting the stringent requirements of hospital environments:
Advanced Therapeutic Persistence Analysis
Our platform provides interactive visualizations that enable healthcare professionals to:
- Monitor therapeutic persistence in real-time
- Identify treatment discontinuation patterns
- Compare the effectiveness of different therapeutic options
- Predict which patients are at higher risk of discontinuation
AI algorithms process large volumes of clinical data to generate actionable insights that improve health outcomes.
Trustworthy, explainable AI
6perAI’s algorithms are trained on real patient data and externally validated. We employ proven machine learning techniques and clinical statistics (for example, Kaplan-Meier survival analysis) that are well-documented in scientific literature. The platform provides clear explanations of the factors contributing to therapy drop-off, helping professionals understand and trust the AI’s insights.
On-premises security
Unlike many cloud solutions, 6perAI is deployed on the hospital’s own infrastructure, keeping all clinical data within your systems. This ensures compliance with GDPR and healthcare privacy regulations while minimizing cybersecurity risks. Sensitive data never leaves your trusted environment.
Easy integration
Thanks to a modular architecture with standard APIs, 6perAI connects readily with electronic health records, pharmacy systems, and other hospital databases. Data ingestion is automated (for example, pulling pharmacy dispensing records or relevant clinical outcomes in the background) and does not interfere with daily operations.
Optimized performance
The platform is designed to handle large volumes of longitudinal data without impacting hospital system performance. It can process years of history for hundreds of patients in seconds, leveraging GPU acceleration when available. Persistence calculations and AI predictions are updated on a scheduled basis (e.g. monthly), with efficient use of resources.
Scalable and customizable
6perAI can be expanded to cover new disease areas or service lines as needed. The AI models retrain to fit the specific characteristics of each institution and patient population. Moreover, the user interface can be configured with additional metrics or views as desired by the team (e.g. to include quality indicators, PROMs, etc.).
Specialized support
Behind 6perAI is a multidisciplinary team of hospital pharmacists, physicians, and data engineers. We provide continuous support, regular software updates, and 24/7 technical assistance. We also incorporate improvements based on emerging evidence and scientific publications in the field of 6P medicine to keep the tool at the forefront of innovation.
Clinical and Economic Benefits
Implementing 6perAI delivers tangible advantages for a private hospital on multiple fronts:
Improved clinical outcomes
By increasing therapeutic persistence, patients achieve better control of their chronic conditions, with fewer relapses and complications. Greater continuity of therapy is linked to lower hospitalization and emergency visit rates as well as improved patient quality of life.
More informed medical decisions
6perAI provides real-world evidence on which therapies work best in the hospital’s own patient population. This supports formulary committees and physicians in selecting optimal medications, prioritizing those with the best efficacy-safety-adherence profile.
Operational optimization
The platform proactively identifies patients at risk of non-adherence (for example, those who miss refills or drop off therapy after a few months). This enables care teams to focus outreach and support where it’s needed most, boosting staff efficiency. Moreover, by integrating with existing systems, 6perAI saves professionals time by automating complex data analyses that would otherwise require manual audits.
Economic impact and ROI
Improving persistence leads to significant cost savings by avoiding wasted spend on prematurely discontinued treatments and preventing expensive complications. For a private hospital, this translates into a stronger hospital ROI – achieving better health outcomes without proportional increases in expenditure.
6P Model: Persistence as a new paradigm
The concept of 6P medicine expands the traditional personalized medicine model by adding Persistence to the 5 classic “P’s” (Personalized, Predictive, Preventive, Participatory, and Population-based).
What is therapeutic persistence?
Therapeutic persistence is the duration of time a patient continues a treatment from initiation until discontinuation. It is distinct from adherence, which usually denotes the percentage of doses or recommendations followed correctly in a given period. Persistence, on the other hand, incorporates adherence within a time frame: it considers not only whether the patient takes their medication as directed, but also for how long they are able to continue it, and it can even factor in the reasons for discontinuation.
Persistence vs. adherence – a practical illustration
Imagine two patients with the same chronic illness: Patient A takes 100% of doses correctly for 6 months, then stops the treatment. Patient B takes only 80% of doses, but continues the treatment for 2 years. Patient A showed higher early adherence, but Patient B demonstrated greater persistence. In the long run, Patient B will likely achieve better health outcomes by staying on therapy long enough to derive sustained benefits.
The importance of measuring persistence
A growing body of evidence supports the importance of measuring persistence. The World Health Organization (WHO) has emphasized that lack of adherence in chronic disease is a critical issue leading to therapeutic failures and higher hospitalization rates. However, average adherence doesn’t tell the whole story. For example, a medication might show 80% adherence, but if many patients discontinue it after the first year, its persistence is low and its real-world benefit is less than expected. In a recent study, the 3-year persistence with a biologic therapy for psoriasis was under 40% despite its proven efficacy, indicating a significant portion of patients stopped the drug within that period. This is where persistence provides incremental value, especially in diseases of high prevalence and therapeutic complexity (expensive treatments, multi-drug regimens, etc.).
Clinical Cases and Scientific References
Clinical evidence and success cases
Proven Results
Persistence Analysis
Monitor the therapeutic persistence of your patients with biological treatments and detect early abandonment patterns.
Outcome Improvement
Identify patients at risk of treatment discontinuation and implement personalized therapeutic interventions to improve clinical outcomes.
Clinical Cases
6P Medicine & Persistence (2023)
A paper in the Journal of Healthcare Quality Research introducing therapeutic persistence as the sixth “P” in modern medicine. This article outlines how persistence provides insight into the real therapeutic value of drugs in chronic diseases and argues for incorporating it into medication assessment.
Persistence in Psoriasis (2024)
A study in Farmacia Hospitalaria on the long-term persistence of secukinumab in patients with moderate-to-severe psoriasis. The results showed persistence rates of 72.7% at 1 year, 51.1% at 2 years, and 39.8% at 3 years, highlighting a progressive decrease in therapy continuation. This work demonstrates the value of analyzing persistence to evaluate the real-world effectiveness and tolerability of a biologic therapy.
Persistence vs. biosimilar switching (2022)
An analysis in Farmacia Hospitalaria that compared the persistence of an originator biologic vs. its biosimilar in inflammatory bowel disease. Differences were observed in retention rates at 1 and 2 years, underscoring the importance of considering persistence when introducing biosimilars or new therapeutic options.
Pricing
Basic License Popular
Includes persistence analysis, basic dashboards, and standard support.
Precio bajo solicitud
Pro License Recommended
Includes all modules, predictive AI, advanced integration, and premium support.
Precio bajo solicitud
Custom License Custom
Custom plans and modules, total integration and dedicated support.
Precio bajo solicitud
Frequently Asked Questions
Contact
For more information, personalized demos, or to discuss your hospital’s needs, please contact us:
- Email: info@6perai.com
- Phone: +34 625 55 69 22
- Website: www.6perai.com